Leadership Overview
Samsung Biologics has 6 executives leading key functions including strategy, finance, marketing, and operations.
Driven by innovation, SAMSUNG BIOLOGICS is dedicated to advancing biopharmaceutical development and manufacturing, impacting global health through its CDMO services and biosimilar research.
Driven by innovation, SAMSUNG BIOLOGICS is dedicated to advancing biopharmaceutical development and manufacturing, impacting global health through its CDMO services and biosimilar research.
Leadership Roles at SAMSUNG BIOLOGICS
Barry Buckland - Chief Executive Officer
Barry Buckland, the Chief Executive Officer at SAMSUNG BIOLOGICS, directs the company's overarching strategy and global operations. Buckland oversees the CDMO business segment, ensuring efficient execution of contract development and manufacturing services for biopharmaceutical products across South Korea, Europe, and the United States. This leadership role involves guiding the company's expansion into new markets and technologies, including antibody-drug conjugates and mRNA products. Buckland's strategic vision focuses on enhancing the company's capabilities in cell line development, process development, and clinical manufacturing. By fostering innovation, the Chief Executive Officer ensures Samsung Biologics maintains its position as a leading CDMO, supporting clients from discovery through commercialization. Barry Buckland drives the company's commitment to quality assurance, control, and biosafety testing, underpinning the reliability of its manufacturing processes.
John Rim - President & Chief Executive Officer
John Rim, the President & Chief Executive Officer at SAMSUNG BIOLOGICS, spearheads the company's strategic direction and operational excellence. Rim guides the CDMO business, ensuring the seamless delivery of biopharmaceutical products and services across global markets. This executive leadership involves driving growth in development services, from discovery and cell line development to process development and clinical manufacturing. Rim's focus extends to optimizing aseptic filling, lyophilization, and finishing processes, ensuring product integrity and client satisfaction. The President & Chief Executive Officer also oversees the Biopharmaceutical Development and Commercialization segment, championing the research and commercialization of biosimilar drugs and antibody-drug conjugates. John Rim's leadership ensures Samsung Biologics remains at the forefront of biomanufacturing innovation, supporting the development and production of critical medicines worldwide.
Seungho Ryu - Executive Vice President & Head Chief Financial Officer, The Business Support Center
Seungho Ryu, the Executive Vice President & Head Chief Financial Officer, The Business Support Center at SAMSUNG BIOLOGICS, manages the company's financial health and operational support functions. Ryu oversees all financial planning, budgeting, and reporting, ensuring fiscal responsibility across the CDMO and Biopharmaceutical Development segments. This critical role involves managing capital allocation for research and development initiatives, including the manufacture of mammalian and mRNA products. The Executive Vice President & Head Chief Financial Officer, The Business Support Center also directs the business support center, optimizing administrative and operational processes to enhance overall efficiency. Seungho Ryu's financial acumen is vital for supporting Samsung Biologics' global expansion and its commitment to providing high-quality biopharmaceutical manufacturing services. Ryu ensures robust financial controls are in place to support sustainable growth and investor confidence.
Tae Kim - President and Chair of BOD
Tae Kim, the President and Chair of BOD at SAMSUNG BIOLOGICS, provides high-level strategic oversight and governance for the organization. Kim leads the Board of Directors, guiding the company's long-term vision and ensuring alignment with shareholder interests. This executive position involves setting the strategic direction for both the CDMO business and the Biopharmaceutical Development and Commercialization segments. The President and Chair of BOD plays a crucial role in major corporate decisions, including investments in new technologies and market expansion. Tae Kim's leadership ensures that Samsung Biologics adheres to the highest standards of corporate governance and ethical conduct. Kim's influence is critical in shaping the company's trajectory, fostering innovation, and maintaining its reputation as a global leader in biopharmaceutical manufacturing.
Jiye Nam - Engineer- Chief Marketing Officer, Cell Culture
Jiye Nam, the Engineer- Chief Marketing Officer, Cell Culture at SAMSUNG BIOLOGICS, drives market strategy and commercialization efforts for cell culture-based biopharmaceuticals. Nam leads the marketing initiatives for the CDMO business, focusing on promoting the company's capabilities in discovery, cell line development, and process development. This role involves understanding market dynamics and client needs to position Samsung Biologics as a preferred partner for biopharmaceutical manufacturing. The Engineer- Chief Marketing Officer, Cell Culture oversees the development and execution of marketing campaigns that highlight the company's expertise in aseptic filling, lyophilization, and quality assurance. Jiye Nam's engineering background informs a data-driven approach to marketing, ensuring alignment with the company's technical strengths. Nam's efforts are crucial for expanding market reach and securing new contracts in the competitive biopharmaceutical sector.
Yeonjun Kim - Part Leader, Program Director of Biologics Chief Marketing Officer PM Unit
Yeonjun Kim, the Part Leader, Program Director of Biologics Chief Marketing Officer PM Unit at SAMSUNG BIOLOGICS, directs strategic program management for biologics marketing initiatives. Kim oversees the execution of key marketing projects, ensuring alignment with the company's overall commercial objectives and CDMO service offerings. This leadership position involves coordinating cross-functional teams to deliver successful marketing campaigns and product launches. The Part Leader, Program Director of Biologics Chief Marketing Officer PM Unit focuses on managing the program lifecycle, from planning and resource allocation to risk mitigation and performance tracking. Yeonjun Kim's role is essential for translating marketing strategies into actionable plans that support business development and client engagement. Kim ensures that program objectives are met efficiently, contributing to Samsung Biologics' market presence and growth in the biopharmaceutical industry.
Explore Leadership Teams in Manufacturing
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Company Leadership CK
KP
Emcure Pharmaceuticals Limited is a global pharmaceutical company engaged in the research, development, manufacturing, and marketing of a broad range of pharmaceutical products and healthcare solutions. Headquartered in Pune, India, the organization operates as an international pharmaceutical enterprise with a strong presence in both domestic and global healthcare markets. The company focuses on delivering innovative and affordable medicines that address a wide spectrum of medical conditions and therapeutic needs across the healthcare sector. The organization is driven by a research-focused strategy that emphasizes innovation, scientific advancement, and the development of effective therapeutic solutions. Through its research and development capabilities, Emcure Pharmaceuticals works to discover and formulate medicines that address unmet medical needs and improve patient outcomes. The company’s research initiatives focus on areas such as complex generics, biosimilars, biologics, and specialized pharmaceutical formulations. These research efforts allow the organization to continuously introduce improved therapies and drug delivery systems designed to enhance treatment effectiveness and patient safety.
Company Leadership SM
NS
Hypera SA is a company that operates in the Pharmaceuticals industry. It employs 5000to9999 people and has 1Gto5G of revenue. The company is headquartered in Sao Paulo, Sao Paulo, Brazil.
Company Leadership AR
TR
LM
Founded in 1950 and headquartered in Hortolândia, Brazil, EMS Pharma is a domestic pharmaceutical company. They are a distributor of pharmaceuticals in Brazil.
Company Leadership OS
CM
RC
Frequently Asked Questions Regarding SAMSUNG BIOLOGICS Top Executives and Leadership Team
